ZYMEWORKS INC (ZYME) — insider trading
Health Care · NASDAQ
ZYMEWORKS INC (ZYME) has 21 reported SEC Form 4 insider transactions in our data, including 2 open-market sales among the most recent 21 (latest 2026-10-09).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-10-09 | Schayowitz Adam | Officer (EVP, Head of R&D) | Option exercise / conversion (derivative) | 37,037 | — | $0 | Form 4 |
| 2026-10-09 | Schayowitz Adam | Officer (EVP, Head of R&D) | Open-market sale | 13,832 | $25.85 | $357.6K | Form 4 |
| 2026-10-09 | Schayowitz Adam | Officer (EVP, Head of R&D) | Option exercise / conversion | 37,037 | — | $0 | Form 4 |
| 2026-07-06 | Hollywood Mark | Officer (EVP & Chief Operating Officer) | Grant / award / vesting | 939 | $22.22 | $20.9K | Form 4 |
| 2026-05-13 | Schneider Paul R | Officer (EVP, General Counsel) | Grant / award / vesting (derivative) | 119,000 | — | $0 | Form 4 |
| 2026-05-13 | Schneider Paul R | Officer (EVP, General Counsel) | Grant / award / vesting (derivative) | 178,000 | — | $0 | Form 4 |
| 2026-04-09 | Platshon Scott | Officer (EVP, Chief Business Officer) | Grant / award / vesting (derivative) | 76,000 | — | $0 | Form 4 |
| 2026-04-09 | Platshon Scott | Officer (EVP, Chief Business Officer) | Grant / award / vesting (derivative) | 47,000 | — | $0 | Form 4 |
| 2026-04-09 | Platshon Scott | Officer (EVP, Chief Business Officer) | Grant / award / vesting (derivative) | 70,000 | — | $0 | Form 4 |
| 2026-04-09 | Schayowitz Adam | Officer (See Remarks) | Grant / award / vesting (derivative) | 76,000 | — | $0 | Form 4 |
| 2026-04-09 | Schayowitz Adam | Officer (See Remarks) | Grant / award / vesting (derivative) | 47,000 | — | $0 | Form 4 |
| 2026-04-09 | Schayowitz Adam | Officer (See Remarks) | Grant / award / vesting (derivative) | 70,000 | — | $0 | Form 4 |
| 2026-04-06 | Stafford Kristin | Officer (EVP, Chief Financial Officer) | Grant / award / vesting (derivative) | 50,000 | — | $0 | Form 4 |
| 2026-04-06 | Stafford Kristin | Officer (EVP, Chief Financial Officer) | Grant / award / vesting (derivative) | 119,000 | — | $0 | Form 4 |
| 2026-04-06 | Stafford Kristin | Officer (EVP, Chief Financial Officer) | Grant / award / vesting (derivative) | 178,000 | — | $0 | Form 4 |
| 2026-01-12 | Hollywood Mark | Officer (EVP & Chief Operating Officer) | Grant / award / vesting (derivative) | 66,000 | — | $0 | Form 4 |
| 2026-01-12 | Hollywood Mark | Officer (EVP & Chief Operating Officer) | Grant / award / vesting (derivative) | 47,000 | — | $0 | Form 4 |
| 2026-01-12 | Hollywood Mark | Officer (EVP & Chief Operating Officer) | Grant / award / vesting (derivative) | 70,000 | — | $0 | Form 4 |
| 2026-01-12 | Hollywood Mark | Officer (EVP & Chief Operating Officer) | Option exercise / conversion (derivative) | 17,666 | — | $0 | Form 4 |
| 2026-01-12 | Hollywood Mark | Officer (EVP & Chief Operating Officer) | Open-market sale | 6,120 | $22.67 | $138.8K | Form 4 |
| 2026-01-12 | Hollywood Mark | Officer (EVP & Chief Operating Officer) | Option exercise / conversion | 17,666 | — | $0 | Form 4 |
Ask the chat about ZYME's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: ZYMEWORKS INC (ZYME).
Last updated 2026-10-09 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.